Skip to content

Eikon Therapeutics, Inc. EIKN Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding

Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding at other companies

Portland General Electric logo
Portland General ElectricPOR
$0
GBC
Glacier BancorpGBCI
$0
TPG Inc. logo
TPG Inc.TPG
$0
D.R. Horton logo
D.R. HortonDHI
$0
First American Financial logo
First American FinancialFAF
$0
Vaxcyte, Inc. logo
Vaxcyte, Inc.PCVX
$0

Other financials

Income statement

See full
Operating income-$87.3M-22.3%
Net income-$83.0M-21.6%
EPS (diluted)-$2.46+90.9%

Balance sheet

See full
Cash & equivalents$161.2M-21.2%
Total debt$254.8M
Total equity$550.7M+186%
Total assets$850.8M

Cash flow

See full
Operating cash flow-$89.8M-64.7%
CapEx$262.0K-98.8%
Free cash flow-$90.1M-17.1%

Valuation

See full
Market cap$521.35M

Where this comes from

Reported directly by Eikon Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: Eikon Therapeutics, Inc. ’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Eikon Therapeutics, Inc. 's preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding?
Eikon Therapeutics, Inc. (EIKN) reported preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding of $0 in Q1 2026.
What does preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding mean?
This represents the par value of preferred shares issued by the company, which carry specific rights and preferences over common stock, such as priority in dividend payments or liquidation. Preferred stock is a form of hybrid capital that sits between debt and common equity. If no shares are issued, this value remains at zero.